Analysts Set Axon Enterprise, Inc. (NASDAQ:AXON) PT at $255.36

Axon Enterprise, Inc. (NASDAQ:AXONGet Free Report) has received an average recommendation of “Moderate Buy” from the ten analysts that are currently covering the firm, Marketbeat.com reports. One equities research analyst has rated the stock with a hold rating and nine have issued a buy rating on the company. The average 1 year price target among brokerages that have covered the stock in the last year is $255.36.

Several research firms have recently weighed in on AXON. Raymond James upped their price target on shares of Axon Enterprise from $223.00 to $233.00 and gave the company an “outperform” rating in a report on Wednesday, November 8th. Barclays lifted their price target on shares of Axon Enterprise from $247.00 to $296.00 and gave the company an “overweight” rating in a research report on Tuesday, January 2nd. TheStreet upgraded Axon Enterprise from a “c” rating to a “b” rating in a research note on Tuesday, November 7th. JMP Securities boosted their price objective on Axon Enterprise from $250.00 to $285.00 and gave the stock a “market outperform” rating in a report on Tuesday, February 6th. Finally, Needham & Company LLC reissued a “buy” rating and set a $240.00 price objective on shares of Axon Enterprise in a research note on Friday, February 2nd.

View Our Latest Stock Report on AXON

Axon Enterprise Trading Down 1.6 %

Shares of AXON opened at $266.71 on Friday. The company has a current ratio of 3.15, a quick ratio of 2.78 and a debt-to-equity ratio of 0.44. The stock has a market capitalization of $19.98 billion, a P/E ratio of 136.78 and a beta of 0.90. Axon Enterprise has a 1-year low of $175.37 and a 1-year high of $273.54. The business’s 50-day moving average price is $252.64 and its 200 day moving average price is $223.76.

Insider Buying and Selling

In other news, insider Jeffrey C. Kunins sold 1,796 shares of the company’s stock in a transaction dated Monday, December 18th. The stock was sold at an average price of $253.46, for a total transaction of $455,214.16. Following the completion of the transaction, the insider now directly owns 228,805 shares of the company’s stock, valued at approximately $57,992,915.30. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. In other news, insider Jeffrey C. Kunins sold 1,796 shares of the business’s stock in a transaction dated Monday, December 18th. The stock was sold at an average price of $253.46, for a total value of $455,214.16. Following the completion of the sale, the insider now directly owns 228,805 shares of the company’s stock, valued at approximately $57,992,915.30. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, President Joshua Isner sold 1,400 shares of the company’s stock in a transaction that occurred on Monday, December 4th. The shares were sold at an average price of $229.60, for a total value of $321,440.00. Following the sale, the president now directly owns 353,135 shares of the company’s stock, valued at $81,079,796. The disclosure for this sale can be found here. Insiders sold 44,176 shares of company stock valued at $11,017,910 in the last three months. 6.10% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the company. HB Wealth Management LLC grew its position in Axon Enterprise by 3.9% during the 4th quarter. HB Wealth Management LLC now owns 1,139 shares of the biotechnology company’s stock worth $294,000 after purchasing an additional 43 shares in the last quarter. Envestnet Portfolio Solutions Inc. increased its holdings in shares of Axon Enterprise by 1.1% in the fourth quarter. Envestnet Portfolio Solutions Inc. now owns 3,997 shares of the biotechnology company’s stock valued at $1,033,000 after purchasing an additional 43 shares in the last quarter. UMB Bank n.a. boosted its stake in Axon Enterprise by 11.0% in the fourth quarter. UMB Bank n.a. now owns 444 shares of the biotechnology company’s stock valued at $115,000 after acquiring an additional 44 shares during the last quarter. CWM LLC raised its holdings in shares of Axon Enterprise by 1.8% during the third quarter. CWM LLC now owns 2,669 shares of the biotechnology company’s stock worth $531,000 after acquiring an additional 46 shares during the period. Finally, Lindbrook Capital LLC increased its stake in shares of Axon Enterprise by 43.3% during the 4th quarter. Lindbrook Capital LLC now owns 172 shares of the biotechnology company’s stock worth $44,000 after purchasing an additional 52 shares during the last quarter. 76.52% of the stock is owned by hedge funds and other institutional investors.

About Axon Enterprise

(Get Free Report

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.

Read More

Analyst Recommendations for Axon Enterprise (NASDAQ:AXON)

Receive News & Ratings for Axon Enterprise Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axon Enterprise and related companies with MarketBeat.com's FREE daily email newsletter.